Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Forero

Showing results (31-40 of 179) with videos related to

Pageof 18
Sort By:
The New England Journal of Medicine|November 5, 2010
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomasAnas Younes, Nancy L Bartlett, John P Leonard, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 25, 2003
A novel monoclonal antibody design for radioimmunotherapyAndres Forero, Ruby F Meredith, M B Khazaeli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignanciesSui Shen, Andres Forero, Albert F LoBuglio, et al.
Breast Cancer Research and Treatment|September 15, 2011
Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicityAngelina I Londoño-Joshi, Patsy G Oliver, Yufeng Li, et al.
British Journal of Haematology|April 23, 2016
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapyAndre Goy, Andres Forero, Nina Wagner-Johnston, et al.
Investigational New Drugs|January 5, 2017
First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumorsAndres Forero, Johanna C Bendell, Prasanna Kumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphomaRanjana Advani, Andres Forero-Torres, Richard R Furman, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 28, 2013
Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphomaChristos Vaklavas, Ruby F Meredith, Sui Shen, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 27, 2005
Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administrationAndres Forero, Ruby F Meredith, M B Khazaeli, et al.
Clinical Pharmacology in Drug Development|July 12, 2022
Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's LymphomaAndres Forero-Torres, Jason Claud Chandler, Swaminathan P Iyer, et al.
Pageof 18

Showing results (31-40 of 179) with videos related to

Sort By:
Pageof 18
The New England Journal of Medicine|November 5, 2010
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomasAnas Younes, Nancy L Bartlett, John P Leonard, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 25, 2003
A novel monoclonal antibody design for radioimmunotherapyAndres Forero, Ruby F Meredith, M B Khazaeli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignanciesSui Shen, Andres Forero, Albert F LoBuglio, et al.
Breast Cancer Research and Treatment|September 15, 2011
Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicityAngelina I Londoño-Joshi, Patsy G Oliver, Yufeng Li, et al.
British Journal of Haematology|April 23, 2016
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapyAndre Goy, Andres Forero, Nina Wagner-Johnston, et al.
Investigational New Drugs|January 5, 2017
First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumorsAndres Forero, Johanna C Bendell, Prasanna Kumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphomaRanjana Advani, Andres Forero-Torres, Richard R Furman, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 28, 2013
Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphomaChristos Vaklavas, Ruby F Meredith, Sui Shen, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 27, 2005
Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administrationAndres Forero, Ruby F Meredith, M B Khazaeli, et al.
Clinical Pharmacology in Drug Development|July 12, 2022
Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's LymphomaAndres Forero-Torres, Jason Claud Chandler, Swaminathan P Iyer, et al.
Pageof 18